Stay updated with breaking news from Marginal Zone. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
NEW YORK CITY (dpa-AFX) - Cipla Limited has received final approval for its Abbreviated New Drug Application for Lenalidomide Capsule 5 mg, 10 mg, 15 mg and 25 mg from the FDA. Cipla's Lenalidomide
CIPLA RECEIVES USFDA APPROVAL FOR GENERIC VERSION OF REVLIMID® Mumbai, India/ New Jersey, United States, September 7, 2022: Cipla... | September 7, 2022
Press release content from Business Wire. The AP news staff was not involved in its creation.
Global Orphan Drugs Rare Disease Therapy Market Opportunity Estimated At USD 350 Billion By 2021 Says Kuick Research
Press release content from Business Wire. The AP news staff was not involved in its creation.